These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 11389501)
1. Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Rex JH; Walsh TJ; Nettleman M; Anaissie EJ; Bennett JE; Bow EJ; Carillo-Munoz AJ; Chavanet P; Cloud GA; Denning DW; de Pauw BE; Edwards JE; Hiemenz JW; Kauffman CA; Lopez-Berestein G; Martino P; Sobel JD; Stevens DA; Sylvester R; Tollemar J; Viscoli C; Viviani MA; Wu T Clin Infect Dis; 2001 Jul; 33(1):95-106. PubMed ID: 11389501 [TBL] [Abstract][Full Text] [Related]
2. Counterpoint: alternative trial designs for antifungal drugs--time to talk. Powers JH Clin Infect Dis; 2001 Jul; 33(1):107-9. PubMed ID: 11389502 [No Abstract] [Full Text] [Related]
3. Empirical antifungal treatment: a valid alternative for invasive fungal infection. Vallejo C; Barberán J Rev Esp Quimioter; 2011 Sep; 24(3):117-22. PubMed ID: 21947092 [TBL] [Abstract][Full Text] [Related]
4. Combination antifungal therapy: what can and should we expect? Johnson MD; Perfect JR Bone Marrow Transplant; 2007 Aug; 40(4):297-306. PubMed ID: 17563740 [TBL] [Abstract][Full Text] [Related]
5. Recent advances and challenges in the treatment of invasive fungal infections. Shao PL; Huang LM; Hsueh PR Int J Antimicrob Agents; 2007 Dec; 30(6):487-95. PubMed ID: 17961990 [TBL] [Abstract][Full Text] [Related]
7. Anidulafungin: a new echinocandin for the treatment of fungal infections. Cohen-Wolkowiez M; Benjamin DK; Steinbach WJ; Smith PB Drugs Today (Barc); 2006 Aug; 42(8):533-44. PubMed ID: 16969430 [TBL] [Abstract][Full Text] [Related]
8. The current role of amphotericin B lipid complex in managing systemic fungal infections. Chu P; Sadullah S Curr Med Res Opin; 2009 Dec; 25(12):3011-20. PubMed ID: 19849324 [TBL] [Abstract][Full Text] [Related]
9. [Voriconazole: a new weapon against invasive fungal infections]. Aoun M Rev Med Brux; 2004 Jun; 25(3):166-71. PubMed ID: 15291449 [TBL] [Abstract][Full Text] [Related]
10. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Segal BH; Almyroudis NG; Battiwalla M; Herbrecht R; Perfect JR; Walsh TJ; Wingard JR Clin Infect Dis; 2007 Feb; 44(3):402-9. PubMed ID: 17205448 [TBL] [Abstract][Full Text] [Related]
11. Management of invasive fungal infections: a role for polyenes. Chandrasekar P J Antimicrob Chemother; 2011 Mar; 66(3):457-65. PubMed ID: 21172787 [TBL] [Abstract][Full Text] [Related]
12. Combination therapy for invasive mycoses: evaluation of past clinical trial designs. Sobel JD Clin Infect Dis; 2004 Oct; 39 Suppl 4():S224-7. PubMed ID: 15546122 [TBL] [Abstract][Full Text] [Related]
20. Achievements and goals of the EORTC Invasive Fungal Infections Group. European Organisation for Research and Treatment of Cancer. de Pauw BE; Herbrecht R; Meunier F; Eur J Cancer; 2002 Mar; 38 Suppl 4():S88-93. PubMed ID: 11858972 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]